The global myelodysplastic syndrome treatment market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of 8.9%, during the forecast period (2019-2027). Increasing regulatory approvals to develop and launch of novel drugs indicated for the treatment of myelodysplastic syndrome is expected to drive market growth over the forecast period. For instance, in 2016, Opsona Therapeutics Ltd. received an orphan drug designation from U.S.FDA for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Moreover, in March 2017, FibroGen Inc. received approval from the China Food and Drug Administration (CFDA) for conducting Phase 2/3 trial of drug ‘roxadustat’ in low risk myelodysplastic syndrome patients with anemia.

Browse 32 Market Data Tables and 35 Figures spread through 182 Pages and in-depth TOC on 'Myelodysplastic syndrome treatment market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'

To know the latest trends and insights related to Myelodysplastic syndrome treatment market, click the link Here:

https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775

Increasing adoption of inorganic growth strategies such as collaboration by key players operating in the pharmaceutical industry is expected to drive growth of the myelodysplastic syndrome treatment market. For instance, in October 2016, Dr. Reddy’s Laboratories entered into a strategic collaboration with Gland Pharma to market and distribute diverse portfolio of eight injectable abbreviated new drug applications (ANDAs). Moreover, in December 2018, Celgene Corporation in collaboration with Acceleron Pharma Inc. announced the results from the pivotal, phase 3 MEDALIST trial. Moreover, players in the MDS treatment market such as Celgene is focused on investing in research and development (R&D) of MDS specific drugs and several of their drugs are showing positive results in the clinical trials. For instance, according to the Celgene: May 2017 news findings; company has gained the information about the role of innate immune system in the development of MDS. Celgene is currently focused on R&D to target this particular type of inflammation with medications and therapeutic antibodies, in order to make MDS cells more vulnerable. These factors are expected to drive growth of the myelodysplastic syndrome treatment market over the forecast period.

Key Takeaways of the Global Myelodysplastic Syndrome Treatment Market:

  • The global myelodysplastic syndrome treatment market is expected to exhibit a CAGR of 8.9% during the forecast period (2019–2027), owing to increasing initiatives by major players for development of effective drugs for the treatment of gout. For instance, in 2016, Opsona Therapeutics Ltd. received orphan drug designation for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Moreover, after Celgene lost its U.S. exclusivity for Vidaza, many generic formulations of Vidaza entered in the market.  
  • Furthermore, increasing regulatory approvals for myelodysplastic syndrome treatment drugs is expected to drive the market growth over the forecast period. For instance, in November 2017, Cipla Ltd, received the U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug route of administration (ANDA) for Decitabine injection 50 mg single-use sterile vial, a generic version of Otsuka America Pharmaceutical Inc.’s Dacogen.
  • Major players operating in the global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner